---
title: "VK2735 in Chronic weight management: Mechanism of action"
description: "Formulary evidence on VK2735 in Chronic weight management: Mechanism of action. Topics: Dual agonist of the GLP-1 and GIP receptors, Receptor binding affinity and half-life extension, Physiological rationale for combined GLP-1 and GIP receptor activation, Incretin hormone physiology, and 4 further topics. 8 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description/mechanism-of-action"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: Mechanism of action

<a id="heading-2.1.2.6.1"></a>

## 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

### Dual agonist of the GLP-1 and GIP receptors

> “VK2735 is a wholly owned long-acting dual agonist of the glucagon like peptide-1, or GLP-1 receptor, and the glucose dependent insulinotropic polypeptide, or GIP receptor, in development for the potential treatment of obesity and other metabolic disorders.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-2.1.2.6.1-2"></a>

### Receptor binding affinity and half-life extension

> “VK2735 binds with high affinity to both the GLP‐1 receptor (IC50: 188 nM) and GIP receptor (IC50: 325 nM) (unpublished data, Viking Therapeutics, Inc.).”
> “The VK2735 peptide incorporates the activities of both incretins and contains a side chain that imparts an extended half‐life when administered as a subcutaneous injection.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-2.1.2.6.1-3"></a>

### Physiological rationale for combined GLP-1 and GIP receptor activation

> “Activation of the glucagon-like peptide 1 (GLP-1) receptor has been shown to decrease glucose, reduce appetite, lower body weight, and improve insulin sensitivity in patients with type 2 diabetes, obesity, or both. Concomitant activation of glucose-dependent insulinotropic polypeptide (GIP) receptors may potentiate the satiety and insulin-sensitizing effects of GLP-1 receptor activation, leading to enhanced clinical benefits.”

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

<a id="topic-2.1.2.6.1-4"></a>

### Incretin hormone physiology

> “GLP-1 and GIP are gut hormones secreted from intestinal L cells and K cells, respectively. Together, these hormones account for most of the enhanced insulin secretion observed in healthy adults after a meal.”

Source: [Viking Therapeutics VK2735 pipeline page](https://vikingtherapeutics.com/pipeline/vk2735/)

<a id="topic-2.1.2.6.1-5"></a>

### Selection of VK2735 from an internally developed dual agonist series

> “Viking selected VK2735 from a series of internally developed dual GLP-1/GIP receptor agonists evaluated as part of a program focused on the development of best-in-class therapies for metabolic diseases.”

Source: [Viking Therapeutics VK2735 pipeline page](https://vikingtherapeutics.com/pipeline/vk2735/)

<a id="topic-2.1.2.6.1-6"></a>

### Subcutaneous formulation: peptide administered once weekly

> “VK2735 is a peptide GLP-1 and GIP dual agonist administered Once Weekly”

Source: [ClinicalTrials.gov NCT07104500](https://clinicaltrials.gov/study/NCT07104500)

<a id="topic-2.1.2.6.1-7"></a>

### Oral formulation: same peptide administered once daily as a tablet

> “VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily”

Source: [ClinicalTrials.gov NCT07868835](https://clinicaltrials.gov/study/NCT07868835)

<a id="topic-2.1.2.6.1-8"></a>

### One molecule in both formulations

> “An important factor in this differentiation is the ability to use the same dual-acting GLP-1 and GIP coagonist molecule in both subcutaneous and oral formulations.”

Source: [Viking Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/401860-q4-2025/)

<a id="topic-2.1.2.6.1-9"></a>

### Peptide sequence, structure, and oral absorption technology

No evidence found.

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
